阿米洛利对急性脑梗死患者血清Glu、TGF-β1水平的影响
发布时间：2019-01-28 11:52
【摘要】：目的：（1）研究对象随机分为盐酸阿米洛利组(治疗组)及基础治疗组（对照组），探讨阿米洛利对不同程度急性脑梗死患者神经功能缺损程度的影响。（2）检测两组患者不同时期血清Glu、TGF-β1的水平，结合阿米洛利的作用机制探讨阿米洛利在脑梗死发生发展中的作用。 方法：将60例急性脑梗死患者随机分为治疗组(盐酸阿米洛利片2.5mg次，，1次日，晨起口服)和对照组，两组均给予基础及对症治疗，持续用药14天，于入院当天、入院后第14天采用酶联免疫吸附法（ELISA）分别测定2组患者血清Glu、TGF-β1的水平,同时对其神经功能缺损程度进行评分，另对入院时所有患者血清Glu、TGF-β1水平进行两变量相关性分析。数据采用SPSS16.0进行统计分析，P0.05差异有统计学意义。 结果：治疗前，2组患者神经功能缺损程度NIHSS评分、血清Glu及TGF-β1含量的差异无统计学意义(P＞0.05)。治疗后各项试验室指标较治疗前有明显改善。治疗后对照组及治疗组的神经功能缺损评分分别为{(9.00±4.35)vs(8.10±3.89)}分，两组比较差异无统计学意义(P＞0.05)；治疗后对照组及治疗组的血清Glu水平分别为{(64.77±14.60) vs(57.36±13.42)}μmol/L，两组比较差异有统计学意义(P＜0.05)；治疗后对照组及治疗组的血清TGF-β1水平分别为{(26.36±6.06)vs(34.81±7.36)}pg/ml，两组比较差异有统计学意义(P＜0.05)；治疗前对所有患者血清Glu与TGF-β1含量做线性相关分析，结果显示二者呈负相关（r=-0.230），Y=42.979-0.23X。即急性脑梗死患者血清TGF-β1含量随Glu的增多呈下降趋势（P＜0.05）。 结论：（1）阿米洛利组与基础治疗组患者的神经功能缺损程度评分（NIHSS评分）较治疗前有降低。（2）治疗后两组患者血清Glu水平较治疗前均显著降低，但治疗组较对照组降低明显。（3）两组患者血清TGF-β1水平较治疗前显著增高，但治疗组较对照组增高明显。（4）急性脑梗死患者血清TGF-β1含量随Glu的增多呈下降趋势，两者呈负相关。阿米洛利对急性脑梗死患者的预后有一定的改善作用。
[Abstract]:Objective: (1) the subjects were randomly divided into two groups: amiolol hydrochloride group (treatment group) and basic treatment group (control group). To investigate the effect of amilolol on the degree of neurological deficit in patients with acute cerebral infarction. (2) to detect the level of serum Glu,TGF- 尾 1 in two groups of patients at different stages. To explore the role of amiloride in the occurrence and development of cerebral infarction combined with the mechanism of amiloride. Methods: sixty patients with acute cerebral infarction were randomly divided into two groups: treatment group (2.5mg group) and control group. Both groups were given basic and symptomatic treatment for 14 days. On the 14th day after admission, the level of serum Glu,TGF- 尾 1 was measured by enzyme linked immunosorbent assay (ELISA) in both groups, and the degree of neurological impairment was evaluated. The serum Glu, of all patients was also evaluated on admission. TGF- 尾 1 level was analyzed by two variable correlation analysis. Data using SPSS16.0 statistical analysis, P0.05 differences were statistically significant. Results: there was no significant difference in NIHSS score, serum Glu and TGF- 尾 1 levels between the two groups before treatment (P > 0. 05). After treatment, the laboratory indexes were significantly improved compared with those before treatment. After treatment, the neurological impairment scores of the control group and the treatment group were (9.00 卤4.35) vs (, 8.10 卤3.89)}, respectively. There was no significant difference between the two groups (P > 0. 05). After treatment, the serum Glu levels of the control group and the treatment group were (64.77 卤14.60) vs (卤57.36 卤13.42)} 渭 mol/L, respectively. The serum TGF- 尾 1 levels in the control group and the treatment group were (26.36 卤6.06) vs (34.81 卤7.36)} pg/ml, respectively. The serum Glu and TGF- 尾 1 levels in all patients were analyzed by linear correlation analysis before treatment. The results showed that there was a negative correlation between the two levels (r-0.230) and YT 42.979-0.23X. That is, serum TGF- 尾 1 content decreased with the increase of Glu in patients with acute cerebral infarction (P < 0. 05). Conclusion: (1) the NIHSS score of patients in amilolol group and basic treatment group was lower than that before treatment. (2) after treatment, the serum Glu level in both groups was significantly lower than that before treatment. But the serum TGF- 尾 1 level in the treatment group was significantly lower than that in the control group. (3) the serum TGF- 尾 1 level in the two groups was significantly higher than that in the control group, but the serum TGF- 尾 1 level in the treatment group was significantly higher than that in the control group. (4) the serum TGF- 尾 1 level in the patients with acute cerebral infarction decreased with the increase of Glu. There was a negative correlation between the two. Amiloride can improve the prognosis of patients with acute cerebral infarction.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R743.3
本文编号：2417033
[Abstract]:Objective: (1) the subjects were randomly divided into two groups: amiolol hydrochloride group (treatment group) and basic treatment group (control group). To investigate the effect of amilolol on the degree of neurological deficit in patients with acute cerebral infarction. (2) to detect the level of serum Glu,TGF- 尾 1 in two groups of patients at different stages. To explore the role of amiloride in the occurrence and development of cerebral infarction combined with the mechanism of amiloride. Methods: sixty patients with acute cerebral infarction were randomly divided into two groups: treatment group (2.5mg group) and control group. Both groups were given basic and symptomatic treatment for 14 days. On the 14th day after admission, the level of serum Glu,TGF- 尾 1 was measured by enzyme linked immunosorbent assay (ELISA) in both groups, and the degree of neurological impairment was evaluated. The serum Glu, of all patients was also evaluated on admission. TGF- 尾 1 level was analyzed by two variable correlation analysis. Data using SPSS16.0 statistical analysis, P0.05 differences were statistically significant. Results: there was no significant difference in NIHSS score, serum Glu and TGF- 尾 1 levels between the two groups before treatment (P > 0. 05). After treatment, the laboratory indexes were significantly improved compared with those before treatment. After treatment, the neurological impairment scores of the control group and the treatment group were (9.00 卤4.35) vs (, 8.10 卤3.89)}, respectively. There was no significant difference between the two groups (P > 0. 05). After treatment, the serum Glu levels of the control group and the treatment group were (64.77 卤14.60) vs (卤57.36 卤13.42)} 渭 mol/L, respectively. The serum TGF- 尾 1 levels in the control group and the treatment group were (26.36 卤6.06) vs (34.81 卤7.36)} pg/ml, respectively. The serum Glu and TGF- 尾 1 levels in all patients were analyzed by linear correlation analysis before treatment. The results showed that there was a negative correlation between the two levels (r-0.230) and YT 42.979-0.23X. That is, serum TGF- 尾 1 content decreased with the increase of Glu in patients with acute cerebral infarction (P < 0. 05). Conclusion: (1) the NIHSS score of patients in amilolol group and basic treatment group was lower than that before treatment. (2) after treatment, the serum Glu level in both groups was significantly lower than that before treatment. But the serum TGF- 尾 1 level in the treatment group was significantly lower than that in the control group. (3) the serum TGF- 尾 1 level in the two groups was significantly higher than that in the control group, but the serum TGF- 尾 1 level in the treatment group was significantly higher than that in the control group. (4) the serum TGF- 尾 1 level in the patients with acute cerebral infarction decreased with the increase of Glu. There was a negative correlation between the two. Amiloride can improve the prognosis of patients with acute cerebral infarction.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R743.3
【参考文献】
相关期刊论文 前7条
1 杨梅;胡治平;;TGF-β_1、Caspase-3与脑损伤缺血再灌注的相互关系[J];医学临床研究;2006年02期
2 张三妹;李光来;;阿米洛利对大鼠脑缺血再灌注损伤后线粒体SDH的影响[J];临床医药实践杂志;2008年01期
3 庄稼英;;2012年ADA糖尿病诊疗指南(一)[J];糖尿病天地(临床);2012年02期
4 ;北满特殊钢集团有限责任公司[J];特殊钢;2003年05期
5 张中兴,卢红,张萍,宋景贵,张帆,刘麦仙;脑梗死后血、脑脊液中兴奋性氨基酸变化与神经功能缺失的关系[J];中国临床康复;2003年25期
6 ;脑卒中患者临床神经功能缺损程度评分标准（1995）[J];中华神经科杂志;1996年06期
7 张三妹;李光来;;阿米洛利对大鼠脑缺血再灌注损伤后ATP酶的影响[J];中西医结合心脑血管病杂志;2008年02期
本文编号：2417033
本文链接：https://www.wllwen.com/yixuelunwen/shenjingyixue/2417033.html
最近更新
教材专著
